Cardiogeni PLC was incorporated on 28 December 2016 and registered in England and Wales under the Companies Act 2006 with company number 10541091. The registered office address is Celixir House, Innovation Way, Stratford-Upon-Avon, England, CV37 7GZ.

The Company is subject to the UK Takeover Code and adheres to the QCA Code.

The Board of Directors are responsible for carrying out the Company’s objectives, implementing its business strategy and the overall supervision of the Company’s activities. The Board provides leadership within a framework of prudent and effective controls. The Board established the corporate governance framework of the Company and has overall responsibility for setting the Company’s strategic aims, defining the business plan and strategy and managing the financial and operational resources of the Company.

The Board, which will meet not less than six times a year with formally constituted Audit, Remuneration, Nomination and Compliance committee meeting twice per year. The Board will ensure that procedures, resources and controls are in place to ensure that AQSE Growth Market Access Rulebook compliance by the Company is operating effectively at all times and that the Directors are communicating effectively with the Company’s AQSE Corporate Adviser regarding the Company’s ongoing compliance with the AQSE Growth Market Access Rulebook and in relation to all announcements, notifications and potential transactions.